aid: adimab
name: Adimab
description: 'Adimab is a private biotechnology company founded in 2007, headquartered
  in Lebanon, New Hampshire, with a west coast office in Mountain View, California.
  It operates a proprietary yeast-based antibody discovery and engineering platform
  that combines fully human synthetic and immune libraries to generate specific, stable
  and developable IgGs, heavy-chain antibodies (HCAbs), multispecifics, T-cell engagers
  and T-cell receptors. Adimab deliberately runs no internal therapeutic pipeline,
  instead partnering with biopharma companies through funded discovery programs, platform
  transfer and non-exclusive program deals. The company reports more than 140 industry
  partnerships since 2009, 675+ therapeutic programs initiated, 90+ clinical programs
  and 6 commercial products. Adimab publishes no public developer API, SDK, developer
  portal or machine-readable API contract; its capabilities are delivered as laboratory
  discovery services and licensed platform transfer under partnership agreements.'
url: https://raw.githubusercontent.com/api-evangelist/adimab/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
image: https://adimab.com/wp-content/uploads/2025/08/ADIMAB_LOGO.svg
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Biotechnology
- Life Sciences
- Antibody Discovery
- Protein Engineering
- Drug Discovery
- Pharmaceuticals
- Research Services
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/adimab-domain-security.yml
- type: LLMsTxt
  url: llms/adimab-llms.txt
- type: Website
  url: https://adimab.com/
- type: About
  url: https://adimab.com/about-us/
- type: Contact
  url: https://adimab.com/contact-us/
- type: Careers
  url: https://adimab.com/careers/open-positions/
- type: PressReleases
  url: https://adimab.com/news-events/press-releases/
- type: Events
  url: https://adimab.com/news-events/events/
- type: Resources
  url: https://adimab.com/resources/
- type: Publications
  url: https://adimab.com/resources/?_resources_type=publications
- type: WhitePapers
  url: https://adimab.com/resources/?_resources_type=white-papers
- type: PrivacyPolicy
  url: https://adimab.com/privacy-policy/
- type: TermsOfService
  url: https://adimab.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/adimab-llc/
- type: Leadership
  url: https://adimab.com/leadership/
- type: SecondaryMarket
  url: https://www.hiive.com/securities/adimab-stock
x-enrichment:
  date: '2026-08-02'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-api-surface:
  public_api: false
  checked: '2026-08-02'
  note: >-
    No developer portal, API documentation, OpenAPI/Swagger/AsyncAPI/GraphQL
    contract, MCP server, A2A agent card, /.well-known surface, or first-party
    SDK on npm/PyPI/RubyGems/crates.io. Adimab delivers antibody discovery as a
    laboratory service and licensed platform transfer, not as an API.